Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND‐1 and XTEND‐Kids Studies
Open Access
- 18 March 2025
- journal article
- Published by Wiley in Haemophilia
- Vol. 31 (3) , 391-400
Abstract
Introduction: The Phase 3 studies, XTEND‐1 (NCT04161495) and XTEND‐Kids (NCT04759131), showed once‐weekly efanesoctocog alfa provided high‐sustained factor VIII (FVIII) activity levels that translated into highly effective bleed prevention in patients with severe haemophilia A. Aim: This analysis evaluated the efficacy and safety of efanesoctocog alfa for perioperative management during XTEND‐1 and XTEND‐Kids. Methods: Patients undergoing major or minor surgery were to receive a single preoperative 50 IU/kg dose, with additional 30 or 50 IU/kg doses every 2–3 days as needed following major surgery. Outcomes assessed included FVIII activity levels, number and dose of efanesoctocog alfa injections, surgeon's/investigator's assessment of haemostatic response, total factor consumption, estimated blood loss, number and type of blood transfusions, and safety. Results: In XTEND‐1, 11 adults/adolescents underwent 12 evaluable major surgeries (6 orthopaedic). Eleven surgeries had one preoperative dose (median [range]: 49.9 [13–52] IU/kg); one had no preoperative dose. Median (range) total consumption from Day −1 to 14 was 163.3 (45–361) IU/kg. In XTEND‐Kids, two children underwent major surgery with a single preoperative loading dose (60.4 and 61.9 IU/kg). Across trials, 15 adults/adolescents underwent 18 minor surgeries and 8 children underwent 9 minor surgeries, with a single preoperative dose or no preoperative dose (5 surgeries in adults/adolescents). Haemostatic response was rated excellent for all surgeries. No surgeries required blood transfusion. No safety concerns or inhibitor development was reported. Conclusion: Efanesoctocog alfa provided highly effective perioperative protection in patients with severe haemophilia A. Trial Registration : XTEND‐1: NCT04161495 https://clinicaltrials.gov/study/NCT04161495 ; XTEND‐Kids: NCT04759131 https://clinicaltrials.gov/study/NCT04759131Keywords
This publication has 17 references indexed in Scilit:
- Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia ANew England Journal of Medicine, 2024
- Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia AExpert Review of Hematology, 2023
- Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfaResearch and Practice in Thrombosis and Haemostasis, 2023
- Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia ANew England Journal of Medicine, 2023
- Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studiesResearch and Practice in Thrombosis and Haemostasis, 2022
- Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trialsHaemophilia, 2020
- Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trialThrombosis Research, 2019
- Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trialHaemophilia, 2019
- Safety and efficacy of BAY 81‐8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programmeHaemophilia, 2016
- Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trialsHaemophilia, 2014